Sanofi Consumer Healthcare India Limited announced the results of its postal ballot conducted under Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on April 23, 2026. The postal ballot sought member approval for four ordinary resolutions related to related party transactions and remuneration matters. Mr. Omkar Dindorkar, Partner at M/s. MMJB & Associates LLP, Practicing Company Secretaries, served as the Scrutinizer for the process and submitted his report on April 23, 2026.

The postal ballot voting period commenced on March 24, 2026, at 9:00 a.m. IST and concluded on April 22, 2026, at 5:00 p.m. IST. The total number of shareholders on the record date stood at 50,742. National Securities Depository Limited (NSDL) provided the remote e-voting facility for the postal ballot process.

All four resolutions were approved with an overwhelming majority by the members of the company. The detailed voting results are as follows:

The total number of shares held across all categories was 23,030,622. For the resolutions related to related party transactions, Promoter and Promoter Group did not vote as per Regulation 23(4) of Listing Regulations, which prohibits related parties from voting on such resolutions. Public Institutions and Public Non-Institutions participated actively in the voting process.

For the remuneration-related resolutions, Promoter and Promoter Group cast 16,414,217 votes, all in favour. Public Institutions cast 4,490,436 votes with 100% support for the Non-Executive Director remuneration resolution and 99.9334% support for the Managing Director remuneration amendment. Public Non-Institutions cast 21,899 votes for the Non-Executive Director resolution and 21,879 votes for the Managing Director resolution.

The Scrutinizer confirmed that there were no invalid votes, abstained votes, or less votes cast on the above resolutions. The resolutions were passed with the requisite majority. The company submitted the voting results signed by the Company Secretary, along with the Scrutinizer's Report dated April 23, 2026, to both BSE Limited and National Stock Exchange of India Limited. The company's scrip code on BSE is 544250 and the trading symbol on NSE is SANOFICONR.

Sanofi Consumer Healthcare India Limited conducted its inaugural institutional investor meet on March 24, 2026, presenting a comprehensive overview of its business transformation and strategic roadmap following its demerger from Sanofi. The event, led by Managing Director Himanshu Bakshi and CFO Richard D'Souza, marked a significant milestone for the company as an independent entity.

Business Performance and Portfolio Strength

The company demonstrated strong financial performance with key metrics highlighting its market position:

Sanofi Consumer Healthcare's portfolio comprises market-leading brands across key therapeutic categories. Avil holds the number one volume position in its category, while Allegra ranks third by value. Combiflam maintains its position as the fifth-largest brand in the pain management category, and DePURA has secured a top-five position in the Vitamin D segment.

Strategic Transformation and Growth Vision

The management outlined a fundamental shift from traditional pharmaceutical operations to a fast-moving consumer health (FMCH) model. This transformation focuses on three core pillars: winning through brand equity, leveraging self-choice opportunities, and substantial brand building investments.

Bakshi emphasized the company's evolution: "We had a single minded objective, which was all about reigniting profitable growth because this was a vertical or division which had immense opportunity in the waiting."

Financial Performance Highlights

The company reported strong growth metrics for 2025:

Strategic Growth Initiatives

Sanofi Consumer Healthcare has identified three key levers for future growth:

Healthcare Professional Engagement

The company plans to double its doctor reach through face-to-face interactions in 2026, expanding beyond the current 350 medical representatives. Additionally, digital reach will extend to 50,000 HCPs, focusing on pediatricians, allergologists, chest physicians, and general practitioners.

Consumer Engagement and Digital Strategy

Significant investments in brand building and social media campaigns have commenced, with AI-enabled creative development and digital-first demand generation strategies. The company has initiated direct consumer communication for the first time, educating consumers about category differences and product benefits.

Market Access and Distribution

Direct retail coverage expansion by 2X is planned for 2026, with enhanced in-store visibility and multiple display points. The company is also developing e-commerce and modern trade channels, though these currently contribute single-digit percentages to overall business.

Innovation Pipeline and Product Development

The company continues evaluating strong propositions across existing categories, with Allegra D representing a recent successful launch. Management indicated ongoing discussions about incorporating additional products from the global Opella portfolio into the listed entity.

Organizational Development

Sanofi Consumer Healthcare has undergone significant organizational restructuring, building a performance-driven culture with KPI-focused evaluation systems. The company achieved recognition as one of the most preferred workplaces and increased women employee diversity by more than two times.

Market Opportunities and Category Potential

The management highlighted substantial growth opportunities in core categories:

• Allergy: 3 out of 10 people have suffered from allergies in the last six months
• Pain Management: 9 out of 10 people have experienced pain episodes
• Vitamin D: 7 out of 10 Indians are deficient in Vitamin D

With 53 million people accessing online health information and 1 in 4 consumers self-medicating, the company sees significant potential for category expansion and consumer education initiatives.

Operational Independence and Global Support

Bakshi emphasized the company's operational autonomy: "It is a very empowered country business. India is a key geography for investment. A lot of initiatives are India First now." The company maintains complete P&L ownership while benefiting from Opella's global scale, R&D capabilities, and technology resources. Nearly 100% of production occurs in India, ensuring supply chain independence.

The investor meet concluded with a Q&A session addressing various strategic and operational aspects, demonstrating management's commitment to transparency and stakeholder engagement as the company pursues its growth objectives in the Indian consumer healthcare market.